Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.62 +0.97 (+2.08%)
Streaming Delayed Price Updated: 12:40 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
These 2 Dividend ETFs Are a Retiree's Best Friend ↗
Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends. 
Via The Motley Fool
Topics Artificial Intelligence Bonds ETFs
News headline image
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Stay informed with the top movers within the S&P500 index on Friday. ↗
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Friday. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? ↗
Investors stepped back into beaten-down tech names Friday, with the Nasdaq 100 rising 0.6% by midday in New York, staging a modest rebound after Thursday's sharp selloff. 
Via Benzinga
News headline image
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy ↗
Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026. 
Via Benzinga
News headline image
Friday's session: gap up and gap down stock in the S&P500 index ↗
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Bristol Myers Slumps After Its Heart Condition Study Gets The Boot ↗
An independent data monitoring committee said the company's treatment for acute coronary syndrome was likely to fail in testing. 
Via Investor's Business Daily
News headline image
Discover the top S&P500 movers in Friday's pre-market session. ↗
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
BMY Stock Slumps 5% After It Scraps Heart Drug Study ↗
The decision follows an analysis by an independent data monitoring committee that the trial is unlikely to meet its key goal. 
Via Stocktwits
News headline image
Update on Phase 3 Librexia ACS Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Reasons to Avoid BMY and 1 Stock to Buy Instead
While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their... 
Via StockStory
Topics Stocks
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership. 
Via Benzinga
News headline image
3 Healthcare Stocks Topping a 2025 List of Dividend Yields ↗
Turn health into wealth with these three high-yielding dividend stocks. 
Via The Motley Fool
News headline image
Jim Cramer Is Backing Off Bristol-Myers, But These 2 Chinese Stocks Are Good ↗
"Mad Money" host Jim Cramer discusses Bristol-Myers Squibb, Baidu, Alibaba, Brinker and New Era Energy & Digital. 
Via Benzinga
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results... 
Via MarketMinute
News headline image
Cliff Asness: The Stock Market is Expensive, Not a Bubble – A Call for Rationality in a Less Efficient Market
New York, NY – November 10, 2025 – In a financial landscape often characterized by extremes, Cliff Asness, the influential co-founder of AQR Capital Management, offers a nuanced yet stark assessment of... 
Via MarketMinute
Topics Economy
News headline image
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
News headline image
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization. 
Via Benzinga
News headline image
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' ↗
Cleveland-Cliffs shares gained 1.4% to close at $12.43 on Friday while Bristol-Myers Squibb shares gained 1% to close at $46.07. 
Via Benzinga
News headline image
Bristol Myers Squibb Co (NYSE:BMY) Presents a Compelling Value Investment Case ↗
Bristol Myers Squibb (BMY) offers strong value with a low P/E ratio, high profitability, and a robust 5.38% dividend yield, despite patent challenges. 
Via Chartmill
Topics Intellectual Property
News headline image
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
From Bristol Myers Squibb
Via Business Wire
News headline image
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
News headline image
Bristol-Myers Squibb Co (NYSE:BMY) Offers a Compelling Mix of High Yield and Dividend Growth ↗
Discover Bristol-Myers Squibb (BMY), a top dividend stock with a strong 5.82% yield, consistent growth, and solid profitability for reliable income. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Thursday. ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its... 
Via StockStory
Topics Artificial Intelligence Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.